Xu Yongfu, Han Haixiong, Zhang Fabiao, Lv Shangdong, Li Zhengyu, Fang Zheping
Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China.
Oncol Lett. 2015 Jan;9(1):300-304. doi: 10.3892/ol.2014.2686. Epub 2014 Nov 7.
Human leukocyte antigen (HLA)-F, a non-classical HLA-class I molecule, has attracted attention as an important immunosuppressive molecule in recent years, although the clinical relevance of HLA-F expression in cancer patients remains unclear. In the present study, HLA-F expression in 90 primary hepatocellular carcinoma (HCC) lesions and 55 corresponding adjacent normal liver tissues was analyzed by immunohistochemistry, and the associations between HLA-F expression and clinicopathological parameters and patient survival times were analyzed. Positive HLA-F expression was observed in 47.8% (43/90) of the HCC lesions and in 10.9% (6/55) of the normal liver tissues. HLA-F expression in HCC lesions was significantly correlated with patient gender (P=0.02), and venous or lymphatic invasion (P=0.02). Patients who were HLA-F-positive had worse survival times than those who were HLA-F-negative (P=0.04). The mean overall survival times for HLA-F-negative and -positive patients were 44.2 months [95% confidence interval (CI), 37.7-50.7] and 33.0 months (95% CI, 25.1-40.8), respectively. Multivariate analysis revealed that HLA-F was an independent prognostic factor for HCC patients with a hazard ratio of 2.1 (95% CI, 1.0-4.4). In conclusion, the present study demonstrated that HLA-F expression was associated with poor survival in HCC patients, and is correlated with tumor cell invasion and metastasis.
人类白细胞抗原（HLA）-F是一种非经典的HLA I类分子，尽管HLA-F在癌症患者中的临床相关性仍不明确，但近年来它作为一种重要的免疫抑制分子已引起关注。在本研究中，采用免疫组织化学方法分析了90例原发性肝细胞癌（HCC）病变组织及55例相应的癌旁正常肝组织中HLA-F的表达情况，并分析了HLA-F表达与临床病理参数及患者生存时间之间的关系。在47.8%（43/90）的HCC病变组织及10.9%（6/55）的正常肝组织中观察到HLA-F阳性表达。HCC病变组织中HLA-F的表达与患者性别（P=0.02）及静脉或淋巴管侵犯（P=0.02）显著相关。HLA-F阳性患者的生存时间短于HLA-F阴性患者（P=0.04）。HLA-F阴性和阳性患者的平均总生存时间分别为44.2个月[95%置信区间（CI），37.7 - 50.7]和33.0个月（95% CI，25.1 - 40.8）。多因素分析显示，HLA-F是HCC患者的独立预后因素，风险比为2.1（95% CI，1.0 - 4.4）。总之，本研究表明HLA-F表达与HCC患者的不良生存相关，且与肿瘤细胞的侵袭和转移有关。
